Development of A MERS-CoV Replicon Cell Line for Antiviral Screening

Jing Chen1,2 · Bing-Jie Hu1,2 · Kai Zhao1,2 · Yun Luo1,2 · Hao-Feng Lin1,2 · Zheng-Li Shi1

Received: 17 October 2020 / Accepted: 23 November 2020 / Published online: 22 February 2021
© Wuhan Institute of Virology, CAS 2021

Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease with a high mortality of ~35%. The lack of approved treatments for MERS-CoV infection underscores the need for a user-friendly system for rapid drug screening. In this study, we constructed a MERS-CoV replicon containing the Renilla luciferase (Rluc) reporter gene and a stable luciferase replicon-carrying cell line. Using this cell line, we showed that MERS-CoV replication was inhibited by combined application of lopinavir and ritonavir, indicating that this cell line can be used to screen inhibitors of MERS-CoV replication. Importantly, the MERS-replicon cell line can be used for high-throughput screening of antiviral drugs without the need for live virus handling, providing an effective and safe tool for the discovery of antiviral drugs against MERS-CoV.

Keywords Middle East respiratory syndrome coronavirus (MERS-CoV) · Replicon cell line · Antiviral screening · Luciferase reporter gene

Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory syndrome that initially emerged in the Middle East in 2012 and continues to cause epidemic outbreaks globally (Zaki et al. 2012; de Wit et al. 2016). At the end of November 2019, 2494 laboratory-confirmed cases of MERS and 858 deaths were reported in 27 countries, with a mortality rate of ~35% (WHO 2019). Camels are direct sources of MERS-CoV and have been carrying the virus for at least 30 years (Muller et al. 2015). Close contact between humans and camels contributes to the ongoing MERS-CoV epidemic in humans (Azhar et al. 2014; Dudas et al. 2018). However, there are currently no approved antiviral drugs or vaccines against MERS-CoV infection, underscoring the urgent need for an efficient antiviral inhibitor screening method.

MERS-CoV, a member of the family Coronaviridae, is an enveloped, positive-sense, single-stranded RNA virus. The 5′ end of the genome harbors two large open reading frames (ORFs), ORF1a and ORF1b, which encode polyproteins pp1a and pp1ab. Two viral proteins, 3C-like protease and papain-like protease, process polyproteins to generate 16 mature non-structural proteins. These non-structural proteins are essential for MERS-CoV RNA replication and transcription. At the 3′ end of the genome, several ORFs encode four structural proteins (spike [S], envelope [E], membrane [M], and nucleocapsid [N]) and five accessory proteins (ORF3, ORF4a, ORF4b, ORF5, ORF8b) (van Boheemen et al. 2012). The structural proteins of coronaviruses are related to virus entry, assembly, and release (Siu et al. 2008; Kuo et al. 2016). Furthermore, the N protein has been proven to be essential for coronavirus transcription (Almazan et al. 2004; Zúñiga et al. 2010; Hurst et al. 2013). The accessory proteins mediate virus–host interaction and contribute to viral pathogenicity (Yang et al. 2013; Lee et al. 2019).

Antiviral assays based on infectious MERS-CoV require a high-level biosafety laboratory and are time-consuming. The virus replicon system contains the necessary elements for genome transcription and replication and is non-
infectious, as it lacks viral structural genes. A stable replicon cell line that carries replicon RNA and expresses a reporter gene would allow easy screening for an antiviral inhibition based on luminescent or fluorescent signals (Hertzig et al. 2004; Ge et al. 2008). Thus, the replicon system may be a convenient and safe tool for antiviral drug discovery.

In this study, we constructed a MERS-CoV replicon cDNA clone harboring the Renilla luciferase (Rluc) reporter gene and we developed a stable cell line containing the MERS-CoV replicon with the aim to develop a user-friendly tool for rapid screening of antiviral inhibitors against MERS-CoV. We demonstrate that the MERS-CoV stable cell line can be used for the screening of MERS-CoV replication inhibitors based on Rluc activity detection.

Materials and Methods

Cells and Virus

BHK21 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco). BHK21-MERS-Rep cells were maintained in DMEM supplemented with 10% FBS and 0.3 mg/mL G418 (G418 sulfate, Gibco, USA). MERS-CoV strain EMC/2012 viral RNA was used as a template for cDNA synthesis.

MERS-CoV Replicon Plasmid Construction

The MERS-CoV replicon mainly contains genes encoding the polyproteins pp1a and pp1ab and the N protein, a neomycin phosphotransferase gene (neo), and the Rluc-coding gene (Fig. 1A). The MERS-CoV 5’ UTR and the region containing the polyprotein genes were divided into eight contiguous fragments (fragment A–Fr). The N protein gene under the control of its transcription-regulating sequence (TRS) together with the 3’ UTR was regarded fragment H. Neo and Rluc under the control of TRSs of the E gene and M gene, respectively, were regarded fragments F and G. The cDNA fragments were amplified by PCR using specific primers (primer sequences are available upon request) to introduce BglII and BsmBI restriction cleavage sites to allow unidirectional ligation of all contiguous cDNA fragments. The amplicons were cloned into pGEM-T Easy (Promega). SacII and AscI sites were introduced at the 5’ end of fragment A and the 3’ end of fragment H, respectively. A poly(A) sequence (25 nt) was added to the 3’ end of fragment H. The cDNA clone was constructed as described previously (Zeng et al. 2016). Briefly, to construct a BAC cDNA clone, subclones A–H were digested with restriction enzyme and then ligated into pBAC-CMV vector (Zeng et al. 2016) and transformed into DH10B competent cells. The clones were screened by PCR and verified by restriction enzyme cleavage and sequencing, and the correct clone was designated as pBAC-CMV-MERS replicon.

Detection of the MERS-CoV Replicon in BHK21 Cells

An amount of 1.5 μg of pBAC-CMV-MERS replicon was transfected into BHK21 cells that had been grown to 70% confluence in a 24-well plate. The same amount of empty pBAC-CMV vector was transfected as a negative control. Transfection was conducted using Lipofectamine 3000 (Invitrogen) in Opti-MEM Medium (Gibco) according to the manufacturer’s instructions. After incubation for 4 h, the culture medium was replaced with fresh DMEM containing 10% FBS.

MERS-CoV replicon in transfected BHK21 cells was detected by immunofluorescence assay (IFA). Briefly, at 24 h post transfection, cells were fixed with 4% paraformaldehyde at room temperature for 20 min. The fixed cells were incubated with a house-made rabbit polyclonal antibody against the MERS-CoV N protein. A Cy3-conjugated goat anti-rabbit antibody was used as a secondary antibody. Images were captured under a fluorescence microscope (Invitrogen).

To characterize the replication of the MERS-CoV replicon in BHK21 cells, BHK21 cells in a 24-well plate were transfected with pBAC-CMV-MERS replicon. The transfected cells were lysed at various time points, and Rluc activity was measured. For the Rluc assay, cells were lysed with 1 × Rluc lysis buffer (Promega) at room temperature for 15 min. Rluc activity was measured by mixing 20 μL of cell lysate with 100 μL of substrate (Promega), using a GloMax luminometer (Promega).

Generation and Selection of a MERS-CoV Replicon BHK21 Cell Line

Approximately 5 × 10⁵ BHK21 cells were seeded in a 35-mm dish. After 24 h of incubation, the cells were transfected with 6 μg pBAC-CMV-MERS replicon as described above. At 48 h post transfection, G418 was added to the cell culture medium at a final concentration of 0.3 mg/mL for selection. The culture medium was changed every 3 days. On day 12, the cells were trypsinized and pooled in a T75 flask for further expansion under G418 selection. When the cells had grown into a confluent monolayer, they were trypsinized for establishing individual cell clones by gradient dilution. Individual cell clones were initially expanded in individual wells of 96-well plates and were then transferred to individual wells of
24-well plates for further expansion. All expansion steps were under G418 selection. Cells of passage 5 were aliquoted and stored in a liquid nitrogen.

**Analysis of BHK21-MERS-Rep Cells**

The cloned BHK21-MERS-Rep cells were seeded in 24-well plates and incubated for 24 h. Then, cell lysates were prepared for Western blotting and luciferase assay. For Western blotting, the cells were washed twice with PBS and then lysed. MERS-CoV N protein was detected using a house-made mouse monoclonal antibody and HRP-conjugated goat anti-mouse antibody. Rluc activity was measured as described above.

**Drug Inhibition of MERS-CoV Replication**

BHK21-MERS-Rep cells were seeded in 96-well plates at $1.2 \times 10^4$ cells/well and were cultured in DMEM containing 10% FBS and 0.3 mg/mL G418 for 16 h. Lopinavir (Selleck) and ritonavir (Selleck) were a gift from Prof. Gengfu Xiao. The compounds dissolved in DMSO were serially diluted in DMEM containing 10% FBS medium in two-fold increments and were then added to the cells. After 48 h of incubation, the cell culture medium was removed. The cells were washed thrice with PBS and Rluc activity was measured as described above. The 50% effective concentration ($IC_{50}$) was determined as the concentration at which there was a 50% decrease in MERS-CoV replication.
by setting untreated cells as 0% inhibition, using GraphPad 8 (GraphPad).

After treatment with the compounds at different concentration for 48 h, the inhibition of MERS-CoV replication was confirmed by reverse-transcription quantitative PCR (RT-qPCR). BHK21-MERS-Rep cells were harvested and total cellular RNA was isolated using the RNeasy Mini Kit (Qiagen). The RNA was subjected to SYBR green one-step real-time RT-PCR (Vazyme) with primers targeting MERS-CoV N protein gene (forward, 5′-GGGTGTACCTCTTAATGCCAATTC-3′, reverse, 5′-TCTGTCCTGTCTCCGCAAT-3′). The replicon RNA copy number was determined by interpolation using a standard curve generated using a MERS-CoV infectious clone plasmid.

Cytotoxicity Assay in BHK21-MERS-Rep Cells

The cytotoxicity of compounds was measured using CCK-8 assays. BHK21-MERS-Rep cells were seeded in a 96-well plate and cultured for 16 h. Then, the culture medium was removed and fresh medium containing the compounds at different concentrations was added. After 48 h, 10 μL of CCK-8 reagent (MedChem Express) was added to each well and the cells were incubated for another 1 h. The absorbance was read using an Infinite 200 PRO plate reader (Tecan) with a 450-nm filter.

Statistical Analysis

The experiments involved in statistical analysis were performed in triplicate for two or three times. Each data point represents the group mean, and error bars define the SEM. Statistical analysis was performed with GraphPad 8.

Results

Construction and Characterization of MERS-CoV Replicon

The MERS-CoV replicon plasmid was constructed as described in Materials and Methods (Fig. 1A). To characterize the replication of the MERS-CoV replicon, BHK21 cells were transfected with pBAC-CMV-MERS replicon and then analyzed by IFA and Rluc assay. N protein expression was observed in MERS-CoV replicon cDNA clone-transfected BHK21 cells (Fig. 1B), indicating correct transcription and translation of the MERS CoV polyprotein and N genes. Rluc activity in BHK21 cells was measured at different time points. Rluc signal increased as of 6 h post transfection and reached a peak at 48 h post transfection (Fig. 1C), demonstrating replication of the MERS-CoV replicon. Collectively, these findings indicated that MERS-CoV replicon was successfully constructed.
Establishment of the Stable BHK21-MERS-Rep Cell Line Carrying MERS-CoV Replicon RNA

A stable cell line containing MERS-CoV replicon was established as shown in the flowchart in Fig. 2A. BHK21 cells were transfected with pBAC-CMV-MERS replicon and selected with G418. After 12 days of G418 selection, all surviving cells were trypsinized, pooled, and expanded. Subsequently, the expanded cells were diluted and plated in 96-well plates to obtain single cell clones. Finally, eight G418-resistant single colonies were obtained and expanded for analysis of the presence of MERS-CoV replicon.

RLuc activity and viral protein expression were determined in different colonies of MERS-CoV replicon-transfected BHK21 cells. All eight single cell colonies produced $10^5$–$10^6$ RLuc signal, which was approximately $10^3$–$10^4$ fold higher than the signal produced by naive BHK21 cells (Fig. 2B). MERS-CoV N protein expression was detected in all cell clones by Western blotting, and the cell clone 3C6 exhibited the highest protein levels (Fig. 2C). Then the cell clone 3C6 was chosen to use as BHK21-MERS-Rep cell line. Together, these data indicated that a BHK21 cell line stably carrying the MERS-CoV replicon was successfully constructed.

Antiviral Screening Assay with the BHK21-MERS-Rep Cell Line

To test whether BHK21-MERS-Rep cell line can be used for antiviral screening, the antiviral activity of lopinavir/ritonavir was determined in BHK21-MERS-Rep cells. Lopinavir/ritonavir is currently under evaluation in the MIRACLE trial (Arabi et al. 2018; Arabi et al. 2020). RLuc activity decreased upon lopinavir/ritonavir (molar ratio, 4.6:1) treatment in a dose-dependent manner, with a calculated IC50 of 8.34 μmol/L. No obvious cytotoxicity was observed at concentrations below 50 μmol/L (Fig. 3A). Accordingly, the cell numbers in each test group were further normalized. MERS-CoV replicon replication was confirmed by RT-qPCR. MERS-CoV replicon RNA levels decreased in a dose-dependent manner after treatment with lopinavir/ritonavir (Fig. 3B). These data indicated that BHK21-MERS-Rep cell line can be used for antiviral screening based on RLuc signal measurement.

Discussion

The replicon cell line is a safe and convenient tool for antiviral screening. As no infectious virus is used, it can be used in low biosafety-level laboratories. Additionally, the replicon cell line can be used for high-throughput screening. Replicons of coronaviruses, such as SARS-CoV-2, SARS-CoV, and 229E (Hertzig et al. 2004; Almazan et al. 2006; Ge et al. 2008; Zhang et al. 2021), as well as of flaviviruses (Xie et al. 2016; Kato et al. 2019) and hepatitis C virus (Camus et al. 2018) have been widely used.

The replicon we developed and described here can be used for antiviral screening of inhibitors target viral proteases and host cellular factors that are involved in viral replication and transcription. As the MERS-CoV replicon does not contain the structural proteins S, E, and M, this cell line cannot be used for antiviral assays related to virus entry, assembly, and release, as well as the function associated with the accessory proteins such as ORF3, ORF4a, ORF4b and ORF5.

The MERS-CoV replicon expresses the RLuc reporter gene and neomycin resistant gene and needs neomycin selection for the maintenance in cells. In our study, a single clone of replicon-containing was purified and could continually produce the replicon after 20 passages without obvious variations (Supplementary Fig. S1).

In summary, we successfully constructed a MERS-CoV replicon cDNA clone and we developed a stable MERS-CoV replicon cell line. The MERS-CoV replicon cDNA clone can be used for the study of MERS-CoV transcription and replication. The stable MERS-CoV replicon cell is an effective and safe tool for high-throughput screening of antivirals against MERS-CoV.
Acknowledgements  This study was supported by the strategic priority research program of the Chinese academy of sciences (XDB29010101). We thank our lab members and colleagues for helpful supports during this course of work and Professor Gengfu Xiao for providing Lopinavir and Ritonavir inhibitors.

Author Contributions  JC and Z-LS designed the experiments; JC, BJH, KZ, YL and HFL performed experiments; JC performed data analysis; JC and Z-LS wrote the manuscript. Z-LS finalized the article. All authors read and approved the final manuscript.

Compliance with Ethical Standards  

Conflict of interest  The authors declare that they have no conflict of interest.

Animal and Human Rights Statement  This article does not contain any studies with human and animal subjects performed by any of the authors.

References  

Almazan F, Galan C, Enjuanes L (2004) The nucleoprotein is required for efficient coronavirus genome replication. J Virol 78:12683–12688

Almazan F, DeDiego ML, Galan C, Escors D, Alvarez E, Ortego J, Sola I, Zuniga S, Alonso S, Moreno JL, Nogales A, Capisco C, Enjuanes L (2006) Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis. J Virol 80:10900–10906

Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F, AlSaedi A, Mandalour Y, Almekhlafti GA, Sherbeeni NM, Elzein FE, Memon J, Taha Y, Almotairi A, Maghrabi KA, Qusmaq I, Al Bshabshe A, Bharabah A, Shalhoub S, Jose J, Fowler RA, Hayden FG, Hussein MA, The Mtg (2018) Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 19:81

Arabi YM, Asiri AY, Assiri AM, Balkhy HH, Al Bshabshe A, Al Jeraisy M, Mansourah Y, Azzam MHA, Bin Eshaq AM, Al Johani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F, AlSaedi A, Mandalour Y, Almekhlafti GA, Sherbeeni NM, Elzein FE, Memon J, Taha Y, Almotairi A, Maghrabi KA, Qusmaq I, Al Bshabshe A, Bharabah A, Shalhoub S, Jose J, Fowler RA, Hayden FG, Hussein MA, The Mtg (2018) Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 19:81

Azhar EI, El-Kafrawy SA, Farrag SA, Hassan AM, Al-Saeed MS, Hashem AM, Madani TA (2014) Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 370:2499–2505

Camus G, Xu S, Han B, Lu J, DVory-Sobol H, Yu M, Cheng G, Miller MD, Doehle BP, Mo H (2018) Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems. Virology 514:134–141

de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016) SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14:523–534

Dudas G, Carvalho LM, Rambaut A, Bedford T (2018) MERS-CoV spillover at the camel-human interface. Elife 7:e31257

Ge F, Xiong S, Lin FS, Zhang ZP, Zhang XE (2008) High-throughput assay using a GFP-expressing replicon for SARS-CoV drug discovery. Antiviral Res 80:107–113

Hertzog T, Scandella E, Schelle B, Ziebuhr J, Siddell SG, Ludewig B, Thiel V (2004) Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA. J Gen Virol 85:1717–1725

Hurst KR, Koetzner CA, Masters PS (2013) Characterization of a critical interaction between the coronavirus nucleocapsid protein and nonstructural protein 3 of the viral replicase-transcriptase complex. J Virol 87:9159–9172

Kato F, Nio Y, Yagasaki K, Suzuki R, Hijikata M, Miura T, Miyazaki I, Tajima S, Lim CK, Saijo M, Takasaki T, Hishiki T (2019) Identification of inhibitors of dengue viral replication using replication cells expressing secretory luciferase. Antiviral Res 172:104643

Kuo L, Hurst-Hess KR, Koetzner CA, Masters PS (2016) Analyses of Coronavirus Assembly Interactions with Interspecies Membrane and Nucleocapsid Protein Chimeras. J Virol 90:4357–4368

Lee JY, Bae S, Myoung J (2019) Middle East respiratory syndrome coronavirus-encoded ORF8b strongly antagonizes IFN-β promoter activation: its implication for vaccine design. Microbiol 57:803–811

Muller MA, Meyer B, Corman VM, Al-Masri M, Turkistani A, Ritz D, Sieberg A, Abdalbagh S, Bosch BJ, Lattwein E, Alhakeem RF, Assiri AM, AlBarakat AM, Al-Shantigi AM, Al-Tawfiq JA, Wikramaratna P, Alfrabean AA, Drosten C, Memish ZA (2015) Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infectious Diseases 15:559–564

Siu YL, Teoh KT, Lo J, Chan CM, Kien F, Escriou N, Tsao SW, Nicholls JM, Altmeyer R, Peiris JS, Bruzzone R, Nel B (2008) The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol 82:11318–11330

van Boeheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbaliyen AE, Snijder EJ, Fouchier RA (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3:e00473–e00512

WHO (2019) Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/emergencies/mers-cov/en/

Xie X, Zou J, Shan C, Yang Y, Qiu DM, Dallmeier K, Neys J, Shi PY (2016) Zika Virus Replicons for Drug Discovery. ElBioMedicine 12:156–160

Yang Y, Zhang L, Geng H, Deng Y, Huang B, Guo Y, Zhao Z, Tan W (2013) The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 4:951–961

Zaki AM, van Boeheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814–1820

Zeng LP, Gao YT, Ge XY, Zhang Q, Peng C, Yang XL, Tan B, Chen J, Chmura AA, Dazsak P, Shi ZL (2016) Bat Severe Acute Respiratory Syndrome-Like Coronavirus WIV1 Encodes an Extra Accessory Protein, ORF5X, Involved in Modulation of the Host Immune Response. J Virol 90:6573–6582

Zhang Y, Song W, Chen S, Yuan Z, Yi Z (2021) A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2. Antiviral Res 185:104974

Zúñiga S, Cruz JL, Sola I, Mateos-Gómez PA, Palacio L, Enjuanes L (2010) Coronavirus nucleocapsid protein facilitates template switching and is required for efficient transcription. J Virol 84:2169–2175

J. Chen et al.: MERS-CoV Replicon Cell Line 735